Primo specializes in the development, manufacturing, and commercialization of Radiopharmaceutical Drug Conjugates (RDC), driving continuous innovation in the field of cancer precision medicine. Leveraging our international-standard facilities and cutting-edge expertise, we are dedicated to advancing molecular imaging and targeted therapy—bringing new hope and superior treatment outcomes to cancer patients worldwide.
Integrating targeting, diagnostics, and therapeutics, RDC technology represents a next-generation paradigm in targeted cancer therapy. By leveraging targeting molecules such as antibodies or peptides, RDCs deliver radioisotopes precisely to cancer cells. This enables localized radiotherapy that maximizes tumor destruction while significantly minimizing damage to healthy cells.
The RDC structure is composed of four critical elements: Target Ligand, Linker, Chelator, and Radionuclide.
While conventional External Beam Radiation Therapy (EBRT) is an established and effective cancer treatment, it requires high-energy beams to pass through skin and healthy tissue from outside the body.
In contrast, Radionuclide Drug Conjugates (RDC) utilize an endogenous approach. Administered via intravenous injection, the drug targets tumor lesions directly from within, significantly minimizing collateral damage to surrounding healthy organs.
✓ Precision Tumor Targeting with Minimal Side Effects
✓ Controllable Efficacy and Optimized Toxicity Profile
✓ High Potential for Metastatic and Refractory Cancers
As an extension of RDC technology, Radioligand Theranostics (RLT) possesses a unique dual-functionality: by simply swapping the radionuclide, the same molecular conjugate can transition from high-resolution diagnostic imaging to potent targeted therapy.
Diagnostic Precision
Therapeutic Potency
Primo is dedicated to advancing cancer care through the innovation of Radioligand Therapy (RLT). We believe that RLT technology can unlock a broader therapeutic window, providing safer and more effective treatment options compared to existing standards of care.
Primo’s proprietary Radioligand Therapy (RLT) technology facilitates the rapid clearance of radionuclides that do not bind specifically to cancer cells.
Engineered for precision, this technology clears unbound radionuclides significantly faster than existing commercial platforms, effectively expanding the therapeutic window.
We maintain an extensive library of proprietary linker molecules, allowing us to optimize clearance pathways and kinetics tailored to various targeting moieties.
Primo applies this technology across a wide array of molecules and categories—including antibodies and small molecules—continuously innovating to address diverse cancer types and complex clinical challenges.
